CHM — Chimeric Therapeutics Income Statement
0.000.00%
Last trade - 00:00- AU$6.35m
- AU$5.57m
- AU$3.97m
Annual income statement for Chimeric Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | R2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 3.97 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | — | 3.12 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 15.1 | 15.7 | 25.8 | 12.5 | 14.3 |
| Operating Profit | -15.1 | -15.7 | -25.8 | -12.5 | -10.3 |
| Net Income Before Taxes | -15.1 | -15.7 | -25.8 | -12.5 | -10.3 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -15.1 | -15.9 | -25.9 | -12.5 | -10.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -15.1 | -15.9 | -25.9 | -12.5 | -10.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -15.1 | -15.9 | -25.9 | -12.5 | -10.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.08 | -0.044 | -0.06 | -0.018 | -0.007 |
| Dividends per Share |